| Website | clarusventures.com |
| Phone | 617.949.2200 |
| Employees | |
| Description | Venture capital firm |
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds
| Company | Date | Round | Size | Participants |
| Virdante Pharmaceuticals | 10/09 | Series A | $48M | 5 |
| Zogenix | 9/09 | Series B | $51M | 5 |
| NanoString Technologies | 6/09 | Series C | $30M | 3 |
| Lycera | 5/09 | Series A | $36M | 4 |
| Aerovance | 4/09 | Unattributed | $38M | 8 |
| Biolex Therapeutics | 10/08 | Series D | $60M | 12 |
| ESBATech | 8/08 | Series B | $22M | 7 |
| Pearl Therapeutics | 7/08 | Series A | $18M | 4 |
| Taligen Therapeutics | 1/08 | Series B | $65M | 4 |
| Pelikan Technologies | 12/07 | Series F | $69M | 3 |
| Sientra | 4/07 | Series B | $85M | 3 |
| Aerovance | 3/07 | Series C | $60M | 6 |
